Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

MGX

Metagenomi Inc.

May 16 • 04:00PM ET

7.00

Dollar change +0.20
Percentage change 2.94	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI SCHA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	49.61%	Shs Outstand	37.47M	Perf Week	1.60%
Market Cap	262.22M	Forward P/E	-	EPS next Y	-3.18	Insider Trans	5.09%	Shs Float	18.88M	Perf Month	-15.15%
Income	-	PEG	-	EPS next Q	-0.62	Inst Own	28.34%	Short Float	3.76%	Perf Quarter	-42.43%
Sales	-	P/S	-	EPS this Y	83.80%	Inst Trans	-	Short Ratio	5.14	Perf Half Y	-
Book/sh	7.36	P/B	0.95	EPS next Y	2.00%	ROA	-	Short Interest	0.71M	Perf Year	-
Cash/sh	8.74	P/C	0.80	EPS next 5Y	-	ROE	-	52W Range	5.50 - 12.74	Perf YTD	-32.10%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-45.05%	Beta	-
Dividend TTM	-	Quick Ratio	4.75	Sales past 5Y	3569.20%	Gross Margin	-	52W Low	27.27%	ATR (14)	0.64
Dividend Ex-Date	-	Current Ratio	4.75	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	43.85	Volatility	6.08% 9.81%
Employees	236	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	16.83
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	-329.49%	Payout	-	Rel Volume	0.52	Prev Close	6.80
Sales Surprise	42.02%	EPS Surprise	-42.11%	Sales Q/Q	127.13%	Earnings	May 14 AMC	Avg Volume	138.20K	Price	7.00
SMA20	2.13%	SMA50	-22.73%	SMA200	-28.13%	Trades		Volume	72,350	Change	2.94%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

May-14-24 10:54PM	MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results (GlobeNewswire)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Loading…
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novo Holdings A/S	10% Owner	Feb 13 '24	Buy	15.00	800,000	12,000,000	1,739,175	Feb 15 08:38 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGX

Metagenomi Inc.

Upgrade your FINVIZ experience